History of NLEP Leprosy is a chronic infectious disease caused by Mycobacterium leprae. It usually affects the skin and peripheral nerves, but has a wide range of clinical manifestations. The disease is characterized by long incubation period generally 5-7 years and is classified as paucibacillary or mulitbacillary, depending on the bacillary load. Leprosy is a leading cause of permanent physical disability. Timely diagnosis and treatment of cases, before nerve damage has occurred, is the most effective way of preventing disability due to leprosy.
The earliest records of a ‘leprosy like’ disease come from Egypt, dating as far back as 1400 BC. In China and India the first records appeared in the sixth century BC. In China, a disciple of Confucius named Pai- Nie suffered from a disease resembling lepromatous leprosy, which was known at that time as ’li’ or ‘lai’. In India, leprosy was first described in the Susruth Samhita and treatment with ‘chaulmoogra’ oil was known at that time. It is said that leprosy was referred to as Kusht in the Vedic writing, which is how the disease is known as even to this day in India, Nepal, Indonesia, Malaysia and many other countries in South East Asia. Clay statues of leprosy patients were also found in Mesopotamia dating as far as back as 400 BC. Initially, leprosy patients were isolated and segregated. Communities were hostile to them and the patients were also self conscious and afraid to mix with the community. Leprosoria to segregate the patients from the community were built in Europe in the middle ages. Several statutory acts and laws were also enacted during that time against them. A drug “Chaulmoogra” oil was used for leprosy treatment until “Dapsone” was discovered with antileprosy effects during 1940s. It was in 1970s when multi drug therapy (MDT) consisting of Rifampicin, Clofazimine and Dapsone were identified as cure for leprosy which came into wide use from 1982 following the recommendations of WHO. Since then the services for leprosy patients gradually changed from institutional to outpatient care through health centres and field clinics. Gradually the infected and cured leprosy patients began to be accepted by the Community as a result of intensive health education and visibly successful results of MDT.
Milestones in NLEP
• 1955 - Government of India launched National Leprosy Control Programme
• 1983 - Launched National Leprosy Eradication Programme and introduced MDT for treatment.
• 1991 - WHO declaration to eliminate leprosy at global level by 2000.
• 1993 - 2000 - World Bank supported NLEP – I
• 2001 - 2004 - World Bank supported NLEP – II
• 2005 - National programme continues with GOI funds.
• 2005 - India achieved elimination of leprosy at National Level in December’ 05.
Govt. of India started National Leprosy Control Programme in 1955 based on Dapsone domiciliary treatment through vertical units implementing survey education and treatment activities. It was only in 1970s that a definite cure was identified in the form of Multi Drug Therapy. The MDT came into wide use from 1982, following the recommendation by the WHO Study Group, Geneva in October 1981. Govt. of India established a high power committee under chairmanship of Dr. M.S. Swaminathan in 1981 for dealing with the problem of leprosy. Based on its recommendations the NLEP was launched in 1983 with the objective to arrest the disease activity in all the known cases of leprosy. However coverage remained limited due to a range of organizational issues and fear of the disease and the associated stigma. At this stage in view of substantial progress achieved with MDT, in 1991 the World Health Assembly resolved to eliminate leprosy at a global level by the year 2000. In order to strengthen the process of elimination in the country, the first World Bank supported project was introduced in 1993. The 1st Phase of the World Bank supported National Leprosy Elimination Project started from 1993-94 and completed on 31.3.2000. This Project involved a cost of Rs. 550 crores of which World Bank loan was Rs. 292 crores. During this phase, the prevalence rate reduced from 24/10,000 population in 1992 before starting 1st Phase project to 3.7/10,000 by March 2001. The 2nd Phase of World Bank Project on NLEP started for a period of 3 years from 2001-02. The project involve a cost of Rs. 249.8 crore including World Bank loan of Rs. 166.35 Crore and WHO to provide MDT drugs free of cost worth Rs. 48.00 crore. The project successfully ended on 31st Dec. 2004. The National Leprosy Eradication Programme is being continued with Govt. of India funds from January 2005 onwards. Additional support for the programme is continued to be received from the WHO and ILEP organizations. MDT is to be supplied free of cost as of now by NOVARTIS through WHO. In the year 2001, after the global elimination was achieved, a target was reset for the remaining 14 countries to achieve elimination on national basis by December, 2005. India was one of these countries. The National Health Policy, Govt. of India sets the goal of elimination of leprosy i.e. to reduce the no. of cases to < 1/10,000 population by the year 2005. The National Leprosy Eradication Programme took up the challenge with the active support of the State/ UT Governments and dedicated partners in the World Health Organisation, the International Federation of Anti Leprosy Associations (ILEP), the Sasakawa Memorial Health Foundation & the Nippon Foundation, NOVARTIES, DANLEP (1986-2003) and the World Bank (1993-2004).
UPPER CANADA LOWER BOWEL CLINIC INC 1366 Yonge Street, Suite 301 TEL : 416-926-0262 Toronto, Ontario M4T 3A7 FAX: 416-926-0936 Balmoral Medical Arts Facility – west side of Yonge Street, one block south of St. Clair/Yonge subway station COLONOSCOPY PREPARATION PLEASE PLAN WELL AHEAD *** A REFERRAL LETTER FROM YOUR DOCTOR is required if you are a New Patient
Journal of Attention Disorders Current Literature in ADHD Abikoff, H., McGough, J., Vitiello, B., McCracken, J.,less access to print media than their nonreferred peers. Davies, M., Walkup, J., et al. (2005). SequentialNonreferred children whose homes had the same type ofpharmacotherapy for children with comorbid atten-media environment as children with ADHD watched astion deficit/hyper